Compare Roundhill Magnificent Seven ETF (MAGS) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Roundhill Magnificent Seven ETF trades at $73.45 (market cap $5.84B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 10× Roundhill Magnificent Seven ETF's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 36 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| MAGS | TAK | |
|---|---|---|
Market Cap | $5.84B | $58.16B |
Volume | 1,765,091 | 2,467,530 |
Sector | Sector/Thematic | Health |
52-Week High | $73.90 | $19.05 |
52-Week Low | $55.39 | $13.23 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | — | $86.04B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS (Roundhill Magnificent Seven ETF) trades at $73.69, down 0.28% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides equal-weighted exposure to seven mega-cap tech leaders and has delivered 181% returns since launch, though it trails the S&P 500 in 2026 with just 2% YTD gains. Recent news highlights AI-driven momentum but also concerns about the 'Magnificent Seven' theme fracturing as capital spending pressures dividends and buybacks.
The outlook remains cautiously optimistic given AI supercycle potential, but investors face concentration risk in tech and underperformance versus broader markets. Key risks include aggressive AI spending impacting cash flows and shifting investor preference toward semiconductors. Analyst sentiment is mixed, balancing long-term growth prospects against near-term valuation concerns and market rotation trends.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
